Stocktoria
Xilio Therapeutics, Inc. XLO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-22
Xilio Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -95.9% | -954.9% | — | — | — |
| Net margin | -80.1% | -918.0% | — | — | — |
| FCF margin | -12.6% | -290.3% | — | — | — |
| Return on assets | -22.6% | -81.9% | -125.4% | -63.4% | -34.8% |
| Return on equity | -99.3% | -331.0% | -207.5% | -83.5% | -40.9% |
| Current ratio | 2.58 | 2.21 | 3.02 | 5.89 | 15.85 |
| Revenue growth | 589.9% | — | — | — | — |
Source: SEC EDGAR filings · CIK 0001840233 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.